Grace Therapeutics, Inc.

For the period ended Dec 31, 2025. Filed Feb 12, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2025 · Filed Feb 12, 2026

GRCE$1.87+0.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

	December 31, 2025	March 31, 2025
(Expressed in thousands except share data)	$	$
Assets
Current assets:
Cash and cash equivalents	18,672	22,133
Receivables	20	126
Prepaid expenses	519	453
Total current assets	19,211	22,712
Equipment, net	11	15
Intangible assets	41,128	41,128
Goodwill	8,138	8,138
Total assets	68,488	71,993
Liabilities and Stockholders’ equity
Current liabilities:
Trade and other payables	1,284	1,930
Total current liabilities	1,284	1,930
Derivative warrant liabilities	-	1,141
Deferred tax liability	2,312	2,312
Total liabilities	3,596	5,383
Commitments and contingencies (Note 10)
Stockholders’ equity:
Preferred stock, $0.0001 par value per share; 10,000,000 authorized; none issued and outstanding as of December 31, 2025 and March 31, 2025	—	—
Common stock, $0.0001 par value per share; 100,000,000 authorized; 15,474,026 and 13,718,106 shares issued and outstanding as of December 31, 2025 and March 31, 2025, respectively	1	1
Additional paid-in capital	298,231	293,334
Accumulated other comprehensive loss	(6,038)	(6,038)
Accumulated deficit	(227,302)	(220,687)
Total stockholders' equity	64,892	66,610
Total liabilities and stockholders’ equity	68,488	71,993

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.